News Releases

Friday, April 04, 2014

Heart attack gene, MRP-14, triggers blood clot formation

CLEVELAND – Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

Scientists at Case Western Reserve School of Medicine and University Hospitals Case Medical Center have reached a groundbreaking milestone toward this goal. They have studied humans and mice and discovered how MRP-14 generates dangerous clots that could trigger heart attack or stroke, and what happens by manipulating MRP-14. This study describes a previously unrecognized platelet-dependent pathway of thrombosis. The results of this research will appear in the April edition of The Journal for Clinical Investigation (JCI).


Wednesday, March 26, 2014

UH Case Medical Center offers first catheter ablation therapy approved in the U.S. with direct contact force technology for treatment of atrial fibrillation

CLEVELAND University Hospitals (UH) Case Medical Center is among the first in the country to offer the THERMOCOOL®  SMARTTOUCH® Catheter, the first catheter approved by the Food and Drug Administration (FDA) in the U.S. to feature direct contact force technology for the treatment of patients with atrial fibrillation, or Afib.
 
This novel innovation enables doctors to accurately control the amount of contact force applied to the heart wall during radiofrequency catheter ablation procedures. 


Thursday, March 20, 2014

University Hospitals named one of Ethisphere's 2014 World's Most Ethical Companies

CLEVELAND – University Hospitals (UH) has been recognized by the Ethisphere Institute, an independent center of research promoting best practices in corporate ethics and governance, as one of the 2014 World’s Most Ethical Companies®.
 
This is the second time that the UH health system has received this honor (it previously received the recognition in 2012) and it is one of eight health systems worldwide to be named to this year’s list.


Wednesday, March 19, 2014

Harrington Discovery Institute begins 3rd annual grant competition to support drug discovery

CLEVELAND – The Harrington Discovery Institute (HDI) at University Hospitals (UH) Case Medical Center has opened its third annual grant competition to fund and support physician-scientists at major academic medical centers across the nation in their efforts to accelerate promising drug discoveries.
 
The HDI opens an annual grant competition each spring to identify the nation’s most promising medical breakthroughs and to accelerate their usage in patient care. This year, HDI will select up to 12 researchers to receive Harrington Scholar-Innovator grants of $100,000 and will provide significant additional funding based on the needs of the projects. In addition, these Scholar-Innovators will be given access to HDI’s Innovation Support Center that includes a renowned group of industry experts who are charged with helping oversee drug development. Successful initiatives will thus have access to both human and financial capital to further the transition into the commercial realm.


Friday, March 14, 2014

Pancreatic cancer surgery findings presented at Society of Surgical Oncology Cancer Symposium

CLEVELAND – Despite the benefits of surgery for early stage pancreatic cancer, it remains under-utilized for patients with this deadly disease, according to a new national analysis of trends and outcomes. Physician-scientists at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented their findings and strategies to increase rates on March 13 at the Society of Surgical Oncology Cancer Symposium in Phoenix.
 
In an abstract titled “Factors Associated with Failure to Operate for Localized Pancreatic Adenocarcinoma,” the research team used the Surveillance, Epidemiology and End Results (SEER) database to identify factors associated with not receiving surgery in patients with localized pancreatic cancer. A secondary aim was to evaluate the effect of receiving surgery on disease-specific survival. 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.